| SHZAMSTOCKS' FEATURED PROFILES |
|
| FREE
STOCK PICKS IN YOUR EMAIL |
|
|
PROFILES
Welcome to our comprehensive profile on Positron Corp.
(OTCBB: POSC)
|
OVERVIEW
Positron Corp. (the "Company") is a growing healthcare company offering cardiac molecular imaging solutions that will transform the delivery of healthcare through radiopharmaceutical development, advancing medical imaging technology and by introducing unique disease management applications into the market. The company’s molecular imaging systems incorporate patented and proprietary software and hardware technology for the diagnosis and treatment of patients with heart disease. Through the recent acquisition of Dose Shield, Inc., Positron Corp. will now be able to offer a unique combination of low cost medical imaging technology, affordable radiopharmaceutical solutions and disease specific programs / software differentiating themselves from all other medical device manufacturers.
A substantial change in the market landscape is occurring. These changes involve product mix, regulatory requirements, and the expiration of patents on lucrative radiopharmaceutical products.
Positron’s molecular imaging systems, disease management software are focused on cardiology, the largest segment of Nuclear Medicine.
The reoccurring revenue generated each year by the US nuclear cardiology market for radiopharmaceuticals is in excess of $1.2 Billion. The ability to sell radiopharmaceuticals to the end customer significantly increases recurring revenues The nuclear medicine market for our molecular imaging systems and the Nuclear Pharm-Assist® sold to existing radiopharmacies and hospitals approaches 10,000 targets. Positron will focus on further expanding its ability to compete with other imaging device vendors as well as increase its ability to generate reoccurring revenue at higher margins.
Positron is addressing the needs of the cardiac molecular imaging market. The Company's joint venture Neusoft Positron Medical Systems Co. Ltd. based in Shenyang, People's Republic of China provides Positron with a cardiac Positron Emission Tomography (PET) imaging system that can be priced below most, if not all, competitors. . Positron also offers a competitively priced Single Photon Emission Computed Tomograhy (SPECT) imaging system. The PET and SPECT imaging devices complement each other and positions Positron to supply the molecular imaging market with both technologies. Positron has acquired unique expertise and technology through their acquisition of Dose Shield, Inc. to expedite the company’s entry into the radiopharmaceutical market.
Nuclear Pharm-Assist® offers unique delivery methods by creating a first time virtual pharmacy in-house for customers. Positron believes that the market for the Pharm-Assist is immediate due to new sterility regulations for Radiopharmacies across the country.
Positron is currently developing a coronary disease reversal and prevention online management & solution program. This was made possible by Positron’s agreement with Dr. K. Lance Gould and the University of Texas for rights to Dr. Gould’s heart disease reversal diet and comprehensive practice management, patient centric program. The Company believes that its online coronary disease reversal and prevention product will provide a solution for patients, insurers, self insured corporations and thousands of community hospitals looking to differentiate their services, save cost and reducing outward migration of patients to the larger hospitals.
Investment Highlights:
- Early stage of new marketplace created by a market dynamic shift
- Full solutions provider of PET/SPECT/Pharma/Disease management
- Undervalued market capitalization
- Clinically experienced management with proven market success
- Opportunity through NukeMed to capitalize on radiopharmaceutical business shifting trends
- First time in nuclear cardiology history that the most prescribed radiopharmaceuticals are going generic
- JV with Neusoft for Chinese manufacturing and development
|
|
